EUVIMEDEUVIMED entdecken
Crossref

Metabolic characterization of neurogenetic disorders involving glutamatergic neurotransmission

Sofía Illescas, Yaiza Diaz-Osorio, Anna Serradell, Lucía Toro-Soria, Uliana Musokhranova, Natalia Juliá-Palacios, Juliana Ribeiro-Constante, Xavier Altafaj, Mireia Olivella, Mar O'Callaghan, Alejandra Darling, Judith Armstrong und 3 weitere

Journal of Inherited Metabolic Disease · 2024

DOI: 10.1002/jimd.12689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Sofía Illescas und 14 weiteren Autor:innen. Beteiligte Einrichtung: Synaptic Metabolism and Personalized Therapies Lab, Institut de Recerca Sant Joan de Déu, Department of Neurology and MetabERN, Esplugues de Llobrega…. Hauptthemen laut MEDLINE: Synaptic Transmission, Metabolomics. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Fondo Europeo de desarrollo regional (FEDER), European Regional Development Fund (ERDF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study of inborn errors of neurotransmission has been mostly focused on monoamine disorders, GABAergic and glycinergic defects. The study of the glutamatergic synapse using the same approach than classic neurotransmitter disorders is challenging due to the lack of biomarkers in the CSF. A metabolomic approach can provide both insight into their molecular basis and outline novel therapeutic alternatives. We have performed a semi‐targeted metabolomic analysis on CSF samples from 25 patients with neurogenetic disorders with an important expression in the glutamatergic synapse and 5 controls. Samples from patients diagnosed with MCP2, CDKL5‐, GRINpathies and STXBP1‐related encephalopathies were included. We have performed univariate (UVA) and multivariate statistical analysis (MVA), using Wilcoxon rank‐sum test, principal component analysis (PCA), and OPLS‐DA. By using the results of both analyses, we have identified the metabolites that were significantly altered and that were important in clustering the respective groups. On these, we performed pathway‐ and network‐based analyses to define which metabolic pathways were possibly altered in each pathology. We have observed alterations in the tryptophan and branched‐chain amino acid metabolism pathways, which interestingly converge on LAT1 transporter‐dependency to cross the blood–brain barrier (BBB). Analysis of the expression of LAT1 transporter in brain samples from a mouse model of Rett syndrome (MECP2) revealed a decrease in the transporter expression, that was already noticeable at pre‐symptomatic stages. The study of the glutamatergic synapse from this perspective advances the understanding of their pathophysiology, shining light on an understudied feature as is their metabolic signature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Synaptic TransmissionMetabolomicsHumansAnimalsMiceFemaleMaleChildGlutamic AcidChild, PreschoolBiomarkersAdolescentInfantAdultMetabolic Networks and Pathways

Stichwörter der Autor:innen

Rett syndromeSLC7A5metabolomicsneurodevelopmental diseasestryptophan

Substanzen

Glutamic AcidBiomarkers

Autor:innen und Institutionen

  • Synaptic Metabolism and Personalized Therapies Lab, Institut de Recerca Sant Joan de Déu, Department of Neurology and MetabERN, Esplugues de Llobregat, Barcelona, Spain.
  • Neurometabolic Unit, Hospital Sant Joan de Déu, Department of Neurology, Esplugues de Llobregat, Barcelona, Spain.
  • Neurophysiology Laboratory, Department of Biomedicine, Institute of Neurosciences, Faculty of Medicine and Health Sciences, University of Barcelona, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona,…
  • School of International Studies, ESCI-UPF, Barcelona, Spain.
  • Bioinformatics and Bioimaging Group, Faculty of Science, Technology and Engineering, University of Vic-Central University of Catalonia, Vic, Spain.
  • CIBERER-Spanish Biomedical Research Centre in Rare Diseases, Barcelona, Spain.

Förderung

  • Instituto de Salud Carlos III
  • Fondo Europeo de desarrollo regional (FEDER)
  • European Regional Development Fund (ERDF)

Zitieren

APA

Illescas, S., Diaz-Osorio, Y., Serradell, A., Toro-Soria, L., Musokhranova, U., Juliá-Palacios, N., Ribeiro-Constante, J., Altafaj, X., Olivella, M., O'Callaghan, M., Darling, A., Armstrong, J., Artuch, R., García-Cazorla, À., & Oyarzábal, A. (2024). Metabolic characterization of neurogenetic disorders involving glutamatergic neurotransmission. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12689

Vancouver

Illescas S, Diaz-Osorio Y, Serradell A, Toro-Soria L, Musokhranova U, Juliá-Palacios N, et al. Metabolic characterization of neurogenetic disorders involving glutamatergic neurotransmission. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12689

BibTeX
@article{Illescas2024,
  author = {Illescas, Sofía and Diaz-Osorio, Yaiza and Serradell, Anna and Toro-Soria, Lucía and Musokhranova, Uliana and Juliá-Palacios, Natalia and Ribeiro-Constante, Juliana and Altafaj, Xavier and Olivella, Mireia and O'Callaghan, Mar and Darling, Alejandra and Armstrong, Judith and Artuch, Rafael and García-Cazorla, Àngels and Oyarzábal, Alfonso},
  title = {Metabolic characterization of neurogenetic disorders involving glutamatergic neurotransmission},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  doi = {10.1002/jimd.12689}
}
Kostenlos starten →